Production (Stage)
Conduit Pharmaceuticals Inc.
CDT
$2.33
-$0.14-5.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.78M | 12.91M | 10.60M | 8.71M | 6.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.34M | 16.29M | 13.94M | 8.95M | 7.13M |
| Operating Income | -17.34M | -16.29M | -13.94M | -8.95M | -7.13M |
| Income Before Tax | -19.40M | -17.80M | -15.15M | -6.07M | -2.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.40 | -17.80 | -15.15 | -6.07 | -2.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.40M | -17.80M | -15.15M | -6.07M | -2.79M |
| EBIT | -17.34M | -16.29M | -13.94M | -8.95M | -7.13M |
| EBITDA | -13.56M | -9.74M | -5.41M | -- | -- |
| EPS Basic | -272.65 | -324.95 | -287.68 | -116.29 | -55.83 |
| Normalized Basic EPS | -171.50 | -202.63 | -171.27 | -72.68 | -34.89 |
| EPS Diluted | -272.65 | -324.95 | -347.59 | -226.51 | -166.05 |
| Normalized Diluted EPS | -171.50 | -202.63 | -171.35 | -73.17 | -34.83 |
| Average Basic Shares Outstanding | 441.00K | 231.10K | 205.30K | 190.80K | 184.70K |
| Average Diluted Shares Outstanding | 441.00K | 231.10K | 206.60K | 192.60K | 187.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |